• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

OIG Expects Tighter Control on Compounded Drugs in CMS-Approved Hospitals

Article

OIG recommends training for inspectors and amending contracts with stand-alone pharmacies to ensure improved quality and safety.

More than 2 years after drugs contaminated with a virulent fungus killed 64 patients and caused related illnesses in another 687, Medicare-approved hospital accreditors still don't properly oversee contracts hospitals have with compounding pharmacies to assure these drugs are safe, according to an Office of Inspector General report.

It recommends CMS consider requiring 55 practices to use accreditors to oversee compounded sterile preparations.

Link to the complete article on Medpage Today: http://bit.ly/1uY91MX

Related Videos
Philip Mease, MD
Most employees are unprepared to shop for coverage on their own, underscoring the need for stronger decision tools and consumer protections.
Experts warn that ICHRAs could either stabilize or destabilize the individual market, depending on which workers employers shift into these plans.
Where patients live may shape outcomes in hypertrophic cardiomyopathy, with SDOH linked to higher risks of heart failure and arrhythmias.
Eleanor Perfetto, PhD
Tom Kim, chief medical officer, Sound Long-Term Care Management
Related Content
City St. George’s researcher Ateequllah Hayat, PhD, explains newly identified mechanisms behind lapatinib resistance in HER2-positive breast cancer.

New Molecular Drivers of HER2 Breast Cancer Resistance: A Q&A With Ateequllah Hayat, PhD

February 4th 2026
Article

Ateequllah Hayat, PhD, discusses epigenetic rewiring, biomarkers, and emerging strategies to overcome lapatinib resistance in HER2+ breast cancer.

Read More

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

January 20th 2026
Podcast

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

AJMC original research policy

Increased Payments to Medicare Advantage Plans for Dually Eligible Beneficiaries

February 4th 2026
Article

Increasing Medicare Advantage payments for full Medicaid enrollees was not associated with meaningful changes in inpatient or nursing home use.

Read More

2026 Health Care Predictions: AI, GLP-1s, MAHA, DEI: Sachin H. Jain, MD, MBA

2026 Health Care Predictions: AI, GLP-1s, MAHA, DEI: Sachin H. Jain, MD, MBA

January 1st 2026
Podcast

Sachin H. Jain, MD, MBA, discusses 2026 health care predictions, including AI adoption, GLP-1 demand, MAHA growth, DEI’s return, and policy shifts.

Listen

In this Q&A, Na’am Avitzur, MD, discusses how pulmonary fibrosis impacts sexual health and why addressing quality of life matters.

Pulmonary Fibrosis and Sexual Health: A Q&A With Na’ama Avitzur, MD

February 2nd 2026
Article

A European Respiratory Journal study shows pulmonary fibrosis affects sexual function and quality of life, calling for open clinician-patient conversations.

Read More

Kempton Presley, MPH, MS

Contributor: From Outreach to Outcomes—4 Steps to Stronger Medication Adherence

February 2nd 2026
Article

Addressing poor medication adherence should be a top priority in health plans to ensure short- and long-term benefits in health outcomes and financial stability.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.